Feds OK 2. human embryonic stem cell research (AP)

NEW YORK – only the second time, the u.s. Government has adopted the test of human embryonic stem cell treatment in humans — currently rare disease that causes severe Vision will be lost.

Advanced cell technology, biotechnology company based in Santa Monica, Calif., said the study should begin at the beginning of next year, following the green light of the u.s. food and drug administration.

Only the last month of the second biotechnology company Geron Corp., said that it had begun in the preliminary trials in people with spinal cord injuries substances by injecting cells derived from human embryonic stem cells.

Researchers hope to stem cell allows you to create a wide variety of elinpankkien tissues. But human embryos must be destroyed to harvest the cells that you want to change, which has given their use in dispute.

ACT: Stargardt disease experiment focuses on the n, which affects only about 30 000 Americans. But the company hopes that the same approach works similar and more common eye diseases such as age-related macular degeneration, which affects millions.

Stargardt is an inherited disorder that attacks the central tasks such as Visio uses to read and to recognise the face. Some patients to go completely blind, lose even peripheral vision, while others are seriously impaired and can only perceive light or see from their face in front of the hands.

The disease usually begins in adolescence. A key problem is that the cells are not impaired, the composition of toxic waste from the eye, can develop and kill the other cells. Is not addressed to the management.

12 Patients should be treated in accordance with the new healthy cells in the course of the investigation, the composition created from human embryonic stem cells shall be carried out by the laboratory. This is primarily an early stage of the investigation to be tested for reaction to various doses, injecting only one eye of each patient's safety.

"We've also hopefully see some improvement in Visual acuity, but it is a bonus," said Dr. Robert Lanza, Act's Chief Scientific Officer.

Research carried out by the doctor work centers, Massachusetts, New Jersey and Oregon, ACT said.

Stephen Rose, Chief Research Officer of the Foundation's Fighting that awful said, he is "very, very happy" ACT has the right to initiate an investigation.

___

Online:

ACT: http://www.advancedcell.com

Stargardt disease: http://bit.ly/bionhs


View the original article here

Comments

Post a Comment

Popular posts from this blog

Protein folding via charge zippers

Jan. 18, 2013 — Membrane proteins are the "molecular machines" in biological cell envelopes. They control diverse processes, such as the transport of molecules across the lipid membrane, signal transduction, and photosynthesis. Their shape, i.e. folding of the molecules, plays a decisive role in the formation of, e.g., pores in the cell membrane. In the journal Cell, researchers of Karlsruhe Institute of Technology and the University of Cagliari are now reporting a novel charge zipper principle used by proteins to form functional units. "It is fascinating to see the elegant basic principles that are used by nature to construct molecular assemblies," explains Anne Ulrich, Director of the KIT Institute for Biological Interfaces. "A charge zipper between the charged side chains is an entirely unexpected mechanism used by membrane proteins to neutralize their charges such that they can be immersed into hydrophobic cell membranes....
Read more

Lonza: CMC Product Manager

Due to the expansion of Lonza's Analytical Services department we are looking to recruit an Analytical Product Manager. Reporting to the Group Leader you will proactively coordinate internal and external client project activities (analytical CMC development of recombinant proteins) performed within Analytical Services and to provide scientific oversight of data generated for the projects. Responsibilities:      * Primary point of contact for all analytical activities relating to product development and management of analytical development programmes from early phase development through to license application.      * Primary interface to the Program Management Team, AS study directors and internal and external customers.      * Definition, presentation and representation of analytical CMC programmes to customers, potential new customers & external meetings, including oversight of large analytical portfolio projects.      * Design an...
Read more

GlaxoSmithKline (GSK): Esprit Physician Leadership Development Programme

Esprit Physician Leadership Development Programme Are you an MBBS or MD with experience gained in a pharmaceutical, biotech or academic environment eager to become an outstanding leader? An inquisitive mind who would thrive on a diverse, intellectually demanding global leadership programme? Do you want to translate your medical expertise into disease-beating medicines? And help people across the world to do more, feel better and live longer? We are a science-led, global healthcare company that puts patients first. Our business is focused on developing medicines that improve the quality of human life. To meet the future strategic challenges this entails, we need to fast-track the finest medical talent into senior leadership roles within our business. The Esprit Physician programme is an initial three-year, accelerated, multi-disciplinary and individually tailored programme. It is heavily backed by our senior management team, and it will give you incredible standing as a phys...
Read more